Results 261 to 270 of about 110,473 (315)

Clinical Outcomes of Poly(ADP-Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea. [PDF]

Curr Oncol
Ha HI, Yoon HJ, Song C, Kim ET, Suh DS, Kim KH, Na YJ, Song YJ.   +7 more
europepmc   +1 more source

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions. [PDF]

Biomolecules
Bondar D, Karpichev Y.
europepmc   +1 more source

Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in <i>BRCA1/2</i>-Proficient Cancer Cells. [PDF]

Biomedicines
Zhou D, Liu W, Zhang Y, Li C.
europepmc   +1 more source

Excessive exercise elicits poly (ADP-ribose) Polymerase-1 activation and global protein PARylation driving muscle dysfunction and performance impairment. [PDF]

Mol Metab
Crisol BM, Rocha MB, Franco B, Morelli AP, Katashima CK, Junior SJA, Carneiro FS, Braga RR, Brícola RS, de Azambuja G, Costa RG, Esteves AM, Mori MA, Oliveira MCG, Cintra DE, Pauli JR, Larsen FJ, da Silva ASR, Ropelle ER.   +18 more
europepmc   +1 more source

Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis. [PDF]

Technol Cancer Res Treat
Duan Q, Feng Y, Cao L, Hu L, Wang J, Sun F, Meng Q, Zhou M, Yu J, Gao H.   +9 more
europepmc   +1 more source

The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo. [PDF]

BMC Cancer
Sekine Y, Oka D, Ohtsu A, Nakayama H, Miyao T, Miyazawa Y, Arai S, Koike H, Matsui H, Shibata Y, Suzuki K.   +10 more
europepmc   +1 more source

Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications. [PDF]

JCO Precis Oncol
Torrado C, Plummer R, Yap TA.
europepmc   +1 more source

Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development. [PDF]

Pharmaceutics
Pöstyéni E, Gábriel R, Kovács-Valasek A.   +2 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Poly(ADP-Ribose) Polymerase Inhibitors

Current Medicinal Chemistry, 2003
Poly(ADP-ribose) polymerase-1 (PARP-1) is the principal member of the PARP enzyme family consisting of PARP-1 and several recently identified novel poly(ADP-ribosyl)ating enzymes. PARP-1 functions as a DNA damage sensor and signalling molecule. Upon binding to DNA breaks, activated PARP cleaves NAD(+) into nicotinamide and ADP-ribose and polymerizes ...
Garry J, Southan, Csaba, Szabó
openaire   +2 more sources